
USD
$0.00
(0.00%
)At Close (As of Dec 15, 2025)
$12.99M
Market Cap
-
P/E Ratio
-0.26
EPS
$1.96
52 Week High
$0.89
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $8K |
| Total Revenue | $8K |
| Cost Of Revenue | $1.3M |
| Costof Goods And Services Sold | $1.3M |
| Operating Income | -$41M |
| Selling General And Administrative | $6.6M |
| Research And Development | $9.2M |
| Operating Expenses | $41M |
| Investment Income Net | - |
| Net Interest Income | $1.4M |
| Interest Income | $1.4M |
| Interest Expense | $0 |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.3M |
| Income Before Tax | -$23M |
| Income Tax Expense | $5K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$23M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$23M |
| Ebitda | -$22M |
| Net Income | -$23M |
| Field | Value (USD) |
|---|---|
| Total Assets | $20M |
| Total Current Assets | $20M |
| Cash And Cash Equivalents At Carrying Value | $19M |
| Cash And Short Term Investments | $19M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $50K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $0 |
| Other Current Assets | $916K |
| Other Non Current Assets | - |
| Total Liabilities | $7.1M |
| Total Current Liabilities | $7.1M |
| Current Accounts Payable | $164K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | $0 |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | $6.9M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $13M |
| Treasury Stock | - |
| Retained Earnings | -$442M |
| Common Stock | $12K |
| Common Stock Shares Outstanding | $12M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$32M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $347K |
| Capital Expenditures | $14K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $25M |
| Cashflow From Financing | $172K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$23M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $8K |
| Total Revenue | $8K |
| Cost Of Revenue | $1.3M |
| Costof Goods And Services Sold | $1.3M |
| Operating Income | -$41M |
| Selling General And Administrative | $6.6M |
| Research And Development | $9.2M |
| Operating Expenses | $41M |
| Investment Income Net | - |
| Net Interest Income | $1.4M |
| Interest Income | $1.4M |
| Interest Expense | $0 |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.3M |
| Income Before Tax | -$23M |
| Income Tax Expense | $5K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$23M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$23M |
| Ebitda | -$22M |
| Net Income | -$23M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Synlogic Inc. is an innovative clinical-stage biopharmaceutical firm headquartered in Cambridge, Massachusetts, dedicated to developing cutting-edge synthetic biotic drugs aimed at transforming the treatment landscape for cancer, inflammatory, and metabolic disorders. Leveraging its proprietary engineered probiotics platform, the company is advancing a diverse pipeline of therapeutic candidates that promise enhanced efficacy and safety profiles. With its unique approach and commitment to harnessing synthetic biotic technology, Synlogic stands as a compelling opportunity for institutional investors seeking exposure to high-growth prospects within the biotechnology sector.